Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, James O. Lindsay et al.|The Lancet|2022Cited by 383
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
Levosimendan vs. Dobutamine: Outcomes for Acute Heart Failure Patients on β-Blockers in SURVIVEAlexandre Mebazaa, Alain Cohen‐Solal, Markku S. Nieminen et al.|European Journal of Heart Failure|2009Cited by 193
Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart FailureAlain Cohen‐Solal, Alexandre Mebazaa, Damien Logeart et al.|Journal of the American College of Cardiology|2009Cited by 120
Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children 13 to 24 Months Old With Gastroesophageal Reflux DiseaseMelvin B. Heyman, Harland S. Winter, Weijiang Zhang et al.|Journal of Pediatric Gastroenterology and Nutrition|2007Cited by 9